Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

The company is exploring potential partnerships, mergers, or acquisitions with the help of an investment bank.

Mar. 12, 2026 at 5:01pm

Got story updates? Submit your updates here. ›

Aethlon Medical, Inc., a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, has engaged Maxim Group LLC to act as its exclusive financial advisor in evaluating a range of strategic opportunities, including partnerships, mergers, acquisitions or other transactions involving the company.

Why it matters

The engagement of Maxim Group indicates that Aethlon Medical is actively exploring strategic alternatives to potentially enhance shareholder value and further the development of its medical technologies, which include the Hemopurifier platform designed to selectively remove circulating pathogenic targets from biologic fluids.

The details

Aethlon Medical's CEO and CFO, James Frakes, stated that the company is continuing to execute on its development activities, including completing the second cohort of an Australian oncology trial, while also evaluating strategic alternatives with Maxim's assistance. The company has not established a definitive timeline for this evaluation and cannot assure that any transaction will result from the process.

  • Aethlon Medical announced the engagement of Maxim Group LLC on March 12, 2026.

The players

Aethlon Medical, Inc.

A clinical-stage medical device company headquartered in San Diego, California, that is advancing the Hemopurifier technology to address unmet needs in oncology and infectious disease.

Maxim Group LLC

A leading full-service investment bank, securities and wealth management firm headquartered in Midtown Manhattan that is providing financial advisory services to Aethlon Medical.

James Frakes

The Chief Executive Officer and Chief Financial Officer of Aethlon Medical.

Got photos? Submit your photos here. ›

What they’re saying

“The Company continues to execute its development activities, having completed the second cohort of our Australian oncology trial. Safety data from that cohort will be submitted to the independent Data Safety Monitoring Board for review. At the same time, we are evaluating strategic alternatives with the assistance of Maxim as part of our ongoing efforts to assess opportunities available to the Company and its shareholders.”

— James Frakes, Chief Executive Officer and Chief Financial Officer (PR Newswire)

The takeaway

Aethlon Medical's engagement of Maxim Group LLC to explore strategic opportunities highlights the company's proactive approach to evaluating potential partnerships, mergers, or acquisitions that could help advance its medical technologies and maximize value for shareholders.